Arvinas Inc ARVN:NASDAQ

Last Price$74.44NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$55.00 (2)
Ask (Size)$74.65 (6)
Day Low / HighN/A - N/A
Volume1.7 M
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Arvinas Inc ( NASDAQ )

Price: $74.44
Change: -2.02 (2.64%)
Volume: 1.7 M
4:00PM ET 12/03/2021
 
 

Twist Bioscience Corp ( NASDAQ )

Price: $81.14
Change: -9.93 (10.90%)
Volume: 1.0 M
4:00PM ET 12/03/2021
 
 

Ionis Pharmaceuticals Inc ( NASDAQ )

Price: $26.39
Change: +0.24 (0.92%)
Volume: 1.8 M
4:00PM ET 12/03/2021
 
 

Kodiak Sciences Inc ( NASDAQ )

Price: $83.99
Change: -5.63 (6.28%)
Volume: 388.5 K
4:00PM ET 12/03/2021
 
 

Pacific Biosciences of California Inc ( NASDAQ )

Price: $20.47
Change: -1.09 (5.06%)
Volume: 3.2 M
4:00PM ET 12/03/2021
 

Read more news Recent News

Insider Sell: Arvinas
6:20AM ET 11/18/2021 MT Newswires

Ian Taylor, Chief Scientific Officer, on November 15, 2021, sold 20,000 shares in Arvinas (ARVN) for $1,680,746. Following the Form 4 filing with the SEC,...

Insider Sell: Arvinas
6:06AM ET 11/16/2021 MT Newswires

Liam Ratcliffe, Director, on November 10, 2021, sold 134,310 shares in Arvinas (ARVN) for $11,527,510. Following the Form 4 filing with the SEC, Ratcliffe...

Insider Sell: Arvinas
6:03AM ET 11/10/2021 MT Newswires

Liam Ratcliffe, Director, on November 05, 2021, sold 172,079 shares in Arvinas (ARVN) for $16,006,424. Following the Form 4 filing with the SEC, Ratcliffe...

Insider Sell: Arvinas
9:28AM ET 11/04/2021 MT Newswires

John G Houston, Director, President and CEO, on November 01, 2021, sold 40,000 shares in Arvinas (ARVN) for $3,525,724. Following the Form 4 filing with...

View all Commentary and Analysis

Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer
7:10AM ET 11/19/2021 Seeking Alpha

Kymera: Targeting The Protein Degradation Space
7:27AM ET 10/22/2021 Seeking Alpha

Arvinas (ARVN) Investor Presentation - Slideshow
1:22PM ET 10/07/2021 Seeking Alpha

Arvinas: Tremendous Value Increase With Pfizer Mega-Deal, High Potential
11:00PM ET 7/31/2021 Seeking Alpha

Company Profile

Business DescriptionArvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT. View company web site for more details
Address5 Science Park
New Haven, Connecticut 06511
Phone+1.203.535.1456
Number of Employees83
Recent SEC Filing11/17/20214
President, Chief Executive Officer & DirectorJohn G. Houston
Chief Financial OfficerSean A. Cassidy
Chief Scientific OfficerIan Taylor
Chief Medical OfficerRonald Peck

Company Highlights

Price Open$77.44
Previous Close$76.46
52 Week Range$24.51 - 108.47
Market Capitalization$3.9 B
Shares Outstanding52.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.82
Beta vs. S&P 500N/A
Revenue$14.3 M
Net Profit Margin-794.96%
Return on Equity-27.02%

Analyst Ratings as of 12/02/2021

Buy
14
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset